个人简介
David Rimm is a Professor in the Department of Pathology at the Yale University School of Medicine. He completed an MD-PhD at Johns Hopkins University Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. He is board certified in Anatomic Pathology and Cytopathology. At Yale since 1994, Dr. Rimm is the Director of Yale Pathology Tissue Services and the Yale Tissue Microarray Facility. He is a member of the Executive Team in Pathology and serves as the Director of Translational Pathology. His lab group focuses on quantitative pathology using the AQUA® technology invented in his lab with projects related to predicting response to therapy or recurrence or metastasis in breast and lung cancer.The technology has also been used in a series of efforts related to biospecimen science. The work is supported by grants from the NIH, BCRF, and sponsored research agreements from biopharma. He is a member of a number of correlative science committees for multi-institutional breast cancer clinical trials including SWOG, ALLTO, and TEACH.He also serves on the Molecular Oncology committee for the College of American Pathologists (CAP).He is an author of over 300 peer-reviewed papers and 8 patents.He has served on advisory boards for Amgen, Genentech, Novartis, BMS, Perkin Elmer, Dako, ACD, Biocept, OptraScan and Genoptix.He was a scientific co-founder of HistoRx, a digital pathology company (sold to Genoptix in 2012) and Metamark Genetics, a prognostic determinant company.
MD Johns Hopkins University (1989)
PhD Johns Hopkins University (1989)
Resident Yale-New Haven Hospital
Fellow Medical College of Virginia
Board Certification AB of Pathology, Anatomic Pathology (1995)
Board Certification AB of Pathology, Cytopathology (1996)
近期论文
查看导师新发文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
A Quantitative Comparison of Antibodies to Programmed Cell Death Ligand 1
Gaule, P., J. W. Smithy, M. Toki, J. Rehman, F. Patell-Socha, D. Cougot, P. Collin, P. Morrill, V. Neumeister and D. L. Rimm (2016). "A Quantitative Comparison of Antibodies to Programmed Cell Death Ligand 1." JAMA Oncol. Epub Aug 18-2016
A proposal for validation of antibodies
Uhlen, M., A. Bandrowski, S. Carr, A. Edwards, J. Ellenberg, E. Lundberg, D. L. Rimm, H. Rodriguez, T. Hiltke, M. Snyder and T. Yamamoto (2016). "A proposal for validation of antibodies." Nat Methods 13(10): 823-827.
Standardization of Estrogen Receptor Measurement in Breast Cancer Suggests False-Negative Results Are a Function of Threshold Intensity Rather Than Percentage of Positive Cells
Welsh AW, Moeder CB, Kumar S, Gershkovich P, Alarid ET, Harigopal M, Haffty BG, Rimm DL: (2011) Standardization of Estrogen Receptor Measurement in Breast Cancer Suggests False-Negative Results Are a Function of Threshold Intensity Rather Than Percentage of Positive Cells, J Clin Oncol 29, 2978-2984
Cancer and leukemia group B pathology committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues
Rimm DL, Nielsen TO, Jewell SD, Rohrer DC, Broadwater G, Waldman F, Mitchell KA, Singh B, Tsongalis GJ, Frankel WL, Magliocco AM, Lara JF, Hsi ED, Bleiweiss IJ, Badve SS, Chen B, Ravdin PM, Schilsky RL, Thor A, Berry DA: (2011) Cancer and leukemia group B pathology committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues, J Clin Oncol 2011, 29:2282-2290
Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis
Rothberg BE, Bracken MB, Rimm DL (2009).Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis. J Natl Cancer Inst. 101(7):452-474
What brown cannot do for you
Rimm, D.L.. (2006) What brown cannot do for you (commentary) Nat Biotechnol 24, 914-916.
Algorithms for Automated Tissue Microarray Analysis Reveal Novel Disease Sub-classifications. Camp, R.L. Chung, G.G., and Rimm, D.L. (2002) Algorithms for Automated Tissue Microarray Analysis Reveal Novel Disease Sub-classifications. Nature Medicine 8(11):1323-8
Carvajal-Hausdorf DE, Schalper KA, Bai Y, Black J, Santin AD, Rimm DL: Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance. Gynecol Oncol. 2017 Apr; 2017 Feb 11. PMID: 28196634
Smithy JW, Moore LM, Pelekanou V, Rehman J, Gaule P, Wong PF, Neumeister VM, Sznol M, Kluger HM, Rimm DL: Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma. J Immunother Cancer. 2017; 2017 Mar 21. PMID: 28331615
Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders R, Kowalewski A, Rivard C, Rehman J, Batenchuk C, Burns V, Hirsch FR, Wistuba II: A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. JAMA Oncol. 2017 Mar 9; 2017 Mar 9. PMID: 28278348
Moore LM, England A, Ehrlich BE, Rimm DL: Calcium Sensor, NCS-1, Promotes Tumor Aggressiveness and Predicts Patient Survival. Mol Cancer Res. 2017 Mar 8; 2017 Mar 8. PMID: 28275088
Toki MI, Cecchi F, Hembrough T, Syrigos KN, Rimm DL: Proof of the quantitative potential of immunofluorescence by mass spectrometry. Lab Invest. 2017 Mar; 2017 Jan 16. PMID: 28092364
Rehman JA, Han G, Carvajal-Hausdorf DE, Wasserman BE, Pelekanou V, Mani NL, McLaughlin J, Schalper KA, Rimm DL: Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. Mod Pathol. 2017 Mar; 2016 Nov 11. PMID: 27834350
Kluger HM, Zito CR, Turcu G, Baine MK, Zhang H, Adeniran A, Sznol M, Rimm DL, Kluger Y, Chen L, Cohen JV, Jilaveanu LB: PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clin Cancer Res. 2017 Feb 21; 2017 Feb 21. PMID: 28223273
Gao B, Huang C, Kernstine K, Pelekanou V, Kluger Y, Jiang T, Peters-Hall JR, Coquelin M, Girard L, Zhang W, Huffman K, Oliver D, Kinose F, Haura E, Teer JK, Rix U, Le AT, Aisner DL, Varella-Garcia M, Doebele RC, Covington KR, Hampton OA, Doddapaneni HV, Jayaseelan JC, Hu J, Wheeler DA, Shay JW, Rimm DL, Gazdar A, Minna JD: Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. Oncotarget. 2017 Feb 14. PMID: 28052041
Schalper KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, Velcheti V, Gaule P, Sanmamed MF, Chen L, Herbst RS, Rimm DL: Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. Clin Cancer Res. 2017 Jan 15; 2016 Jul 20. PMID: 27440266
Toki MI, Carvajal-Hausdorf DE, Altan M, McLaughlin J, Henick B, Schalper KA, Syrigos KN, Rimm DL: EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma. J Thorac Oncol. 2016 Nov; 2016 Jul 20. PMID: 27449805
Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, Bago-Horvath Z, Bane A, Bedri S, Brock J, Chmielik E, Christgen M, Colpaert C, Demaria S, Van den Eynden G, Floris G, Fox SB, Gao D, Ingold Heppner B, Kim SR, Kos Z, Kreipe HH, Lakhani SR, Penault-Llorca F, Pruneri G, Radosevic-Robin N, Rimm DL, Schnitt SJ, Sinn BV, Sinn P, Sirtaine N, O'Toole SA, Viale G, Van de Vijver K, de Wind R, von Minckwitz G, Klauschen F, Untch M, Fasching PA, Reimer T, Willard-Gallo K, Michiels S, Loi S, Salgado R: Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol. 2016 Oct; 2016 Jul 1. PMID: 27363491
Uhlen M, Bandrowski A, Carr S, Edwards A, Ellenberg J, Lundberg E, Rimm DL, Rodriguez H, Hiltke T, Snyder M, Yamamoto T: A proposal for validation of antibodies. Nat Methods. 2016 Oct; 2016 Sep 5. PMID: 27595404
京公网安备 11010802027423号